Exclusive negotiations with a view to a combination between MédiPôle Partenaires and Elsan
The combination of the two groups would enable accelerated investment in therapeutical and technological innovation and in the development of more integrated healthcare pathways for patients.
The combination would in particular be subject to the approval of competition authorities; its completion would occur in the first half of 2017. In accordance with French law requirements, a works council consultation process will be implemented beforehand.
The acquisition of MédiPôle Partenaires would be financed by Elsan and its shareholders through a combination of equity injection and bank debt.
MédiPôle Partenaires has been informed that the offer contemplates a refinancing of the MédiPôle Partenaires group debt upon completion of the combination; accordingly, the offer includes an undertaking from the offeror pursuant to which , in case of completion of the proposed combination, the senior floating rate notes due 2020 and the 7.00% senior fixed rate notes due 2020 issued by the MédiPôle Partenaires group pursuant to indentures dated June 26, 2014 and May 7, 2013, respectively, would be redeemed in accordance with the applicable provisions of the indentures relating to early redemption.